Biora Therapeutics progresses research collaboration for BioJet platform

Biora Therapeutics (BIOR) announced that its BioJet Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca (AZN). The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption. “We continue to generate very promising results with our BioJet platform, including those from this study, which are enabling us to progress development under the collaboration,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “While many organizations have been working to solve the challenge of oral delivery of large molecules, we believe our approach stands out because of our ability to deliver multi-milligram liquid doses similar to injection, with minimal to no formulation changes.”